RxDoctor Payments Data

Leslie Massey, DO

Gastroenterology · Carson City, NVNPI 1699186585

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 29.6% of the total. 2025 is the largest year on record at $2,017, 2.3 times the $895 reported in 2019.

$5,289in general payments, 2019–2025

Across 211 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$324
  • Gilead$312
  • Madrigal Pharmaceuticals$307
  • Sanofi$307
  • Johnson & Johnson$233
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,12597%
  • Education$1643%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,289 in reported general payments places this provider in the 65th percentile of 103 gastroenterology providers in Nevada.

See all gastroenterology providers in Nevada

Medicare billing

Part B allowed, 2024
$194,494
Medicare patients
749
Services billed
1,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase39$159,920
ZenpepLipase/Protease/Amylase13$70,242
LinzessLinaclotide30$26,855
Dexlansoprazole DrDexlansoprazole14$5,032
Mesalamine14$4,933
Ursodiol22$3,427
Balsalazide Disodium17$3,084
Lubiprostone20$2,933
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates39$2,756
Pantoprazole Sodium171$2,670
Omeprazole157$2,283
Famotidine88$1,601
Dicyclomine Hcl56$1,549
Esomeprazole Magnesium28$1,538
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl52$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,568$186,77569 claims
Aimmune Therapeutics, Inc.Zenpep$147$70,24213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 103 gastroenterology providers in Nevada.

Other gastroenterology in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →